Light Dimension BioMed Secures Tens of Millions in Angel Funding and Prepares Global Launch of First-in-Class In Vivo Flow Cytometry Research Instrument

VCBeat (WeChat ID: vcbeat) has learned that Light Dimension BioMed announced the completion of its angel financing round, exclusively invested by the professional healthcare investment firm Weidu Venture Capital. The funds will be primarily used for R&D investment and clinical technology innovation.

Guangyu Biomedicine was founded by renowned scientists in the international field of optoelectronic biomedicine, with its core team members possessing extensive experience in academic research, product development, and commercialization.

The core technology of Guangyu Biomedical is the internationally pioneering, independently intellectual property-owned in vivo Flow Cytometer (IVFC). Based on this technology, it enables non-invasive, real-time, dynamic, continuous, and quantitative detection/monitoring of target substances such as cells, molecules, and nanoparticles in the circulatory systems of humans or animals without blood sampling. This approach acquires multidimensional research or clinical data, directly reflecting the true molecular, physiological, metabolic, and pharmacological parameters and states within the internal environment of humans or experimental animals. Distinct from traditional ex vivo detection methods, it provides a novel and disruptive technical means for life science research and clinical diagnostics.

The innovation, feasibility, and application value of this technology have been recognized by peers and experts both domestically and internationally. Animal experiments and preliminary clinical studies have been completed, with related research findings published in prestigious international journals such as Nature, Nature Medicine, Cell, Blood, Light: Science & Applications, Cancer Research, and ACS Nano. To date, over 100 academic papers have been published, accumulating a total impact factor of 887, including more than 30 articles with an impact factor above 10.

Guangyu Biomedical’s upcoming IVFC-1000 series of research instruments will be the world’s first commercial instrument based on IVFC technology, pioneering a novel method for in vivo cytology detection and featuring fully independent intellectual property rights.

In terms of clinical applications, Guangyu Biomedical is developing baseIn Vivo Photoacoustic Flow Cytometry Based on the Photoacoustic Effect, this technology enables real-time, dynamic, non-invasive detection of circulating tumor cells in patients’ circulatory systems without the need for blood draws. It will play a significant role in various aspects of diagnosis and treatment, including non-invasive early diagnosis of tumors, dynamic monitoring of metastasis, evaluation of therapeutic efficacy, prognosis assessment, and guidance for medication. Currently, substantial progress has been made in its application to melanoma, with animal experimental data demonstrating excellent performance and achieving the expected outcomes.

Guangyu Biomedical's R&D pipeline is based on“In Vivo Non-Invasive Optical Technology”centered on, with application areas includingDetection(unlabeled pan-cancer CTCs, immune cells, stem cells, platelets, drug molecules, lipid molecules, nanoparticles, etc.) andTreatment(Optical capture of CTCs, optical therapy for Parkinson’s disease, etc.), providing novel optical instruments and solutions for basic scientific research and clinical applications.

Guangyu Biomedical will soon launch clinical research projects on in vivo detection technology at three renowned hospitals in China, and on this basis, conduct product clinical trials and type testing to apply for medical device registration certificates.

Mr. Ji Lei, Co-Founder and CEO of Guangyu BiomedicineStatement: We extend our gratitude to Weidu Venture Capital for its recognition of Guangyu Biomedical’s in vivo flow cytometry (IVFC) technology and our team. With nearly two decades of experience in the scientific instrumentation and medical device industry, I have witnessed the inspiring development trajectory of high-end domestically produced instruments and equipment. However, innovative instruments with fully independent intellectual property rights, particularly optoelectronic biomedical instruments, remain in the early stages of development. Guangyu Biomedical’s in vivo flow cytometry represents a globally pioneering, disruptive technology that will provide novel solutions based on authentic in vivo environments for both fundamental life sciences research and clinical diagnosis, establishing an entirely new dimension distinct from traditional technologies. In the future, Guangyu Biomedical will continue to expand its product pipeline and applications, striving to build a world-class enterprise rooted in China and oriented toward the global market.

Lead Investor in This Round: Weidu Venture CapitalIt is indicated that in vivo flow cytometry represents a globally innovative technology. The in vivo flow cytometry method based on this technology has disrupted traditional ex vivo cell detection methods, with clearly defined scientific and clinical value. Meanwhile, the high-end precision instrument sector, where Guangyu Biomedical Institute operates, is characterized by high entry barriers, aligns with national industrial policies, and constitutes one of the key focus areas of Weidu Venture Capital’s investment strategy. The team’s research achievements hold a prominent academic standing in the field of biomedical photonics, and they have taken the lead in translating this advanced technology into industrial applications, with the expectation of ultimately contributing to the enrichment of modern medical diagnostic methodologies.

Weidu Ventures is a dynamic and youthful venture capital firm specializing in early-stage investments in the healthcare sector. The firm focuses on cross-disciplinary applications of cutting-edge technologies, such as biotechnology and artificial intelligence, within the medical field. It seeks to leverage these innovations to enable more precise, efficient, and intelligent diagnostic and therapeutic solutions, as well as to drive business model innovation. Backed by extensive industry experience and robust medical resources, the Weidu team is dedicated to partnering with its portfolio companies throughout their growth journey, providing comprehensive support at every stage to help entrepreneurs successfully “bridge the gap from vision to realization.”